Get started
Author

Katrin Nowak‐Reppel

Observed names: Katrin Nowak-Reppel, Nowak-Reppel Katrin, Nowak-Reppel, Katrin
ORCID: 0000-0003-4029-099X
Observed ORCID: 0000-0003-4029-099X
OpenAlex ID: A5021012893
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target
2017 · Manuel Ellermann, Ashley Eheim, et al. · ACS Chemical Biology · 56
Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2-d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5
2018 · Duy Nguyen, Clara Lemos, et al. · Journal of Medicinal Chemistry · 47
Characterization of 12 GnRH peptide agonists – a kinetic perspective
2015 · Indira Nederpelt, Victoria Georgi, et al. · British Journal of Pharmacology · 42
PDF
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
2024 · Ulrike Rauh, Guo Wei, et al. · Nature Cancer · 35
PDF
Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women
2020 · Olaf Panknin, Andrea Wagenfeld, et al. · Journal of Medicinal Chemistry · 26
Discovery of BAY-298 and BAY-899: Tetrahydro-1,6-naphthyridine-Based, Potent, and Selective Antagonists of the Luteinizing Hormone Receptor Which Reduce Sex Hormone Levels in Vivo
2019 · Lars Wortmann, Bernhard Lindenthal, et al. · Journal of Medicinal Chemistry · 23
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
2024 · Keith Graham, Philip Lienau, et al. · Cell chemical biology · 18
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo-Active KAT6AB Inhibitor
2024 · Antonius ter Laak, Roman C. Hillig, et al. · Journal of Medicinal Chemistry · 10
PDF
Discovery of BAY 2413555, First Selective Positive Allosteric Modulator of the M2 Receptor to Restore Cardiac Autonomic Balance
2024 · Alexandros Vakalopoulos, Daniel Basting, et al. · Journal of Medicinal Chemistry · 2
Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor
2023 · Gernot Langer, John Scott, et al. · Molecular Pharmacology · 2
PDF
Abstract 506: ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models
2023 · Ulrike Rauh, Guo Wei, et al. · Cancer Research · 1
KAT6A–inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches
2026 · Vera Puetter, Léa Bouché, et al. · Acta Crystallographica Section D Structural Biology
Discovery, Synthesis and Structural Insights into a New Family of Positive Allosteric Modulators for MRGPRX1
2026 · Lauri Louhivuori, Ainoleena Turku-Metsänen, et al. · Research Square
PDF
Abstract 7064: Development of a new class of KAT6A/B inhibitors with in vivo efficacy.
2026 · Antonius ter Laak, Roman Hillig, et al. · Cancer Research
Abstract 4584: Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I and Rho-GTPase signaling
2024 · Keith Graham, Philip Lienau, et al. · Cancer Research
CCDC 2008704: Experimental Crystal Structure Determination
2020 · Panknin, Olaf, Wagenfeld, Andrea, et al. · The Cambridge Structural Database
CCDC 1943802: Experimental Crystal Structure Determination
2019 · Wortmann, Lars, Lindenthal, Bernhard, et al. · The Cambridge Structural Database
Abstract 689: Identification and optimization of novel chemical matter via a structure-based approach resulting in a probe for MTH1
2018 · Marcus Bauser, Anja Giese, et al. · Cancer Research
Works count: 18
Citation count: 262
H-index: 8
I10-index: 8
Year
Topic
Type